Drug Trial Radar · NCT03316599
Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer
Last checked: Nov 20, 2026Latest source record: Aug 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26
Actual
Start
Jan 17, 2018
Primary completion
Oct 10, 2020
Study completion Jul 29, 2021
Sponsor
- Lead sponsor
- Dana-Farber Cancer InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- AVEO Pharmaceuticals, Inc.
- First posted
- Oct 20, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To identify the maximally tolerated dose of ficlatuzumab when combined with nab-paclitaxel and gemcitabine in patients with previously untreated pancreatic cancer.
Conditions
- Pancreatic Cancer
Interventions
GemcitabineDrug
Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
Nab-paclitaxelDrug
Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells
FiclatuzumabDrug
It is selective recombinant humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G subclass 1 monoclonal antibody which blocks the MET tyrosine kinase receptor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Maximum Tolerated Dose of ficlatuzumab when administered in combination with gemcitabine and nab-paclitaxelTime frame: 2 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Massachusetts General Hospital
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.